Safety of beta-agonists with different duration of action in patients with arterial hypertension and broncho-obstructive diseases

Системные гипертензии

Yu A Dolgusheva¹  I E Chazova¹  O Yu Agapova²  K A Zykov² 

[1] A.L.Myasnikov Institute of Clinical Cardiology, Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian Federation;Laboratory of pulmonology Research medical dental Institute, Moscow State Medical and Dental University named after A.I.Evdokimov of Ministry of Health of the Russian Federation;

关键词: arterial hypertension;    chronic obstructive pulmonary disease;    bronchial asthma;    cardiorespiratory pathology;    beta-agonists;   

DOI  :  

来源: DOAJ

【 摘 要 】

Objective. To examine the safety of beta-agonists (BA) with different duration of action in patients with arterial hypertension (AH) and chronic obstructive pulmonary disease (COPD) or bronchial asthma (BA).Materials and methods: 40 patients (22 - male, 18 - female) with AH and COPD and AH and asthma aged 18 years were enrolled and examined initially. At the next three month, patients were treated with 3 types of BA: at the 1st month - with salbutamol (SABA), at the 2nd - with formoterol (LABA), at the 3rd - with indacaterol (ULABA). Initially, after one week and at the end of each month blood pressure (BP) and heart rate (HR) on the visit, oxygen saturation of peripheral blood, computer spirometry, serum potassium in blood, electrocardiogram, were evaluate. Initially, after one week and at the end of three month of treatment with SABA, LABA and ULABA all patients underwent holter monitoring and ambulatory blood pressure 24-monitoring.Results. Baseline, 1-month, 2-month, 3-month BP and HR levels on the visit were similar among all patients ( p =NS). At the end of the 3rd month of treatment with BA different duration of action in patients with AH and COPD daily average systolic BP (SBP) was lowered than initially ( p

【 授权许可】

Unknown